转移性非小细胞肺癌获得性免疫治疗耐药后放疗重振免疫治疗活性:两项机构前瞻性II期单臂试验的汇总分析
该汇总分析纳入48例IV期非小细胞肺癌患者,均在抗PD-(L)1单药治疗获得至少疾病稳定后出现一个或多个可测量病灶进展。对1至4个转移灶行大分割放疗,同时保留一个或多个病灶未处理,放疗后继续原免疫检查点抑制剂治疗直至再次进展或不可接受毒性。中位无进展生存期4.4个月,中位总生存期14.9个月,3个月疾病控制率62.5%,6个月37.5%,≥2级严重不良事件12例(25%),均与放疗无关。
要点
- 48例IV期NSCLC免疫获得性耐药患者接受1-4个转移灶大分割放疗后继续原免疫治疗,中位PFS 4.4个月。
- 中位OS 14.9个月,3个月疾病控制率62.5%,6个月37.5%,45例(93.8%)放疗后继续免疫治疗中位6.2个月。
- ≥2级严重不良事件12例(25%),无放疗相关,4例免疫相关。
核心结论
- 该汇总分析是对转移性NSCLC新获得性免疫治疗耐药背景下放疗作用的前瞻性评估。
- 大分割放疗可支持免疫检查点抑制剂的疗效,从而在初始肿瘤进展后仍允许继续治疗相当一段时间。
研究设计与样本
- 汇总的两机构、II期单臂前瞻性队列研究。
- 纳入IV期NSCLC患者,抗PD-(L)1单药治疗下出现一个或多个可测量病灶进展,且此前至少达到疾病稳定。
- 对1至4个转移灶行大分割放疗,同时保留一个或多个病灶未处理;放疗后继续原免疫检查点抑制剂治疗不变,直至进一步肿瘤进展或不可接受毒性。
- 汇总分析主要终点为无进展生存期,次要终点包括总生存期和毒性。
主要发现
- 共入组48例,平均年龄67.1±9.3岁,50%为男性,72.9%为PD-L1阳性;入组时95.8%患者免疫治疗为一线或二线。
- 大分割放疗针对1个病灶者占93.8%,中位总剂量27.5 Gy,中位6.5 Gy/次。
- 45例(93.8%)放疗后能继续免疫治疗,中位继续时间6.2个月。
- 中位PFS 4.4个月,3个月疾病控制率62.5%,6个月37.5%;中位OS 14.9个月。
- ≥2级严重不良事件12例(25%),其中无放疗相关,4例免疫治疗相关。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The current work aimed to investigate the clinical benefit of radiotherapy in patients with metastatic non-small cell lung cancer (NSCLC) developing acquired resistance to immune checkpoint inhibitors. METHOD: We report on a pooled, two-institution, phase II single-arm prospective cohort study. The study included patients with stage IV NSCLC who showed progression of one or more measurable lesions under anti-PD-(L)1 inhibition alone, after initially having achieved at least stable disease. Hypofractionated radiotherapy (hRT) of one to four metastases was performed, while one or more lesions were kept untreated. Following hRT, treatment with immune checkpoint inhibitors was continued unchanged until further evidence of tumor progression or unacceptable toxicity. Primary endpoint of the pooled analysis was progression-free survival (PFS), secondary endpoints included overall survival (OS) and toxicity. RESULTS: A total of 48 patients were enrolled: mean age was 67.1 ± 9.3 years, 50 % were male and 72.9 % were PD-L1 positive. Immunotherapy was in 95.8 % of patients the first or second line therapy at time of enrollment. hRT was performed to one (93.8 % of cases) or more lesions (median total dose: 27.5 Gy, median 6.5 Gy/fraction). Forty-five patients (93.8 %) were able to continue immunotherapy for a median of 6.2 months following hRT. Median PFS was 4.4 months, with 62.5 % disease control at three months and 37.5 % at six months. Median OS was 14.9 months. Severe adverse events (grade ≥ 2) were reported in 12 cases (25 %), of which none were radiotherapy-related and four were immunotherapy-related. Salvage therapy consisted of chemotherapy (48.8 %) or repeated irradiation (21.9 %). No further tumor treatment was performed in 29.3 % of patients. CONCLUSIONS: The current pooled analysis is a prospective evaluation of the role of radiation therapy for metastatic NSCLC in the setting of newly acquired immunotherapy resistance. Hypofractionated radiotherapy can support the outcome of immune checkpoint inhibitors and thus allow continuation of treatment for a relevant amount of time despite initial tumor progression.
引用
- Popp I, Vaes RDW, Wieten L, et al. Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trials. Radiother Oncol. 2023. PMID: 38070686. doi:10.1016/j.radonc.2023.110048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。